U S Biomedical Systems India Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
- Paid Up Capital ₹ 6.86 M
- Company Age 15 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 685.47%
- Profit Growth -694.12%
- Ebitda 915.44%
- Net Worth -1.60%
- Total Assets -1.53%
About U S Biomedical Systems India
U S Biomedical Systems India Private Limited (USBSIPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 22 December 2009 and has a history of 15 years and two months. Its registered office is in Pondicherry, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 6.86 M, as per Ministry of Corporate Affairs (MCA) records.
Priyadarshini Yaravintelimath and Aroul Djealatchoumanan serve as directors at the Company.
Company Details
- Location
Pondicherry, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74900PY2009PTC002396
- Company No.
002396
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Dec 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pondicherry
Industry
Who are the key members and board of directors at U S Biomedical Systems India?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyadarshini Yaravintelimath  | Director | Current | |
| Aroul Djealatchoumanan | Director | 01-Apr-2014 | Current |
Financial Performance of U S Biomedical Systems India.
U S Biomedical Systems India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 685.47% increase. The company also saw a substantial fall in profitability, with a 694.12% decrease in profit. The company's net worth dipped by a decrease of 1.6%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of U S Biomedical Systems India?
In 2023, U S Biomedical Systems India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at U S Biomedical Systems India?
U S Biomedical Systems India has a workforce of 519 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of U S Biomedical Systems India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped U S Biomedical Systems India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
